Harvard's T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.

TScan Therapeutics, a US-based T-cell immunotherapy developer spun out of Harvard University, has filed for an initial public offering on the Nasdaq Global Market. The company has set a placeholder figure of $100m. Morgan Stanley, Jefferies, Cowen and Barclays Capital are underwriters for the IPO. Founded in 2018, TScan is developing T-cell therapies to target…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.